Related Experiment Video
Updated: Jul 16, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a
Rashmi Ratnam1, Parul Jain2, Ram Awadh Singh Kushwaha3
1Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India.
Background:
The World Health Organization recommends all-oral bedaquiline-based regimens for drug-resistant tuberculosis (DR-TB), including a longer M/XDR-TB regimen (18-20 months) and a shorter RR/MDR-TB regimen (9-11 months). Comparative effectiveness data under routine programmatic conditions remain limited.
Objective:
To compare clinical and microbiological outcomes of longer versus shorter all-oral treatment regimens.
Methods:
We conducted a prospective observational cohort study between January and December 2022. Patients with pulmonary or extrapulmonary RR/MDR-TB were enrolled and treated according to national programmatic guidelines. Six-month culture conversion and end-of-treatment clinical outcomes were compared between longer and shorter all-oral bedaquiline-based regimens using multivariable logistic regression adjusted for pre-specified confounders.
Results:
Of 1427 patients screened, 894 (62.6%) were included; 691 (77.3%) received the longer regimen and 203 (22.7%) the shorter regimen. Baseline demographic and clinical characteristics were broadly comparable, although resistance profiles differed because regimen allocation was guided by drug susceptibility testing and programmatic eligibility criteria. Six-month culture results were available for 778 (87.0%) patients; 96 (10.7%) died and 20 (2.3%) were lost to follow-up. Culture conversion was significantly higher with the longer regimen than the shorter regimen (579/596, 97.1% vs. 146/182, 80.2%; p < 0.001). In intention-to-treat analysis, favorable outcomes occurred in 525/691 (76.0%) patients receiving the longer regimen and 135/203 (66.5%) receiving the shorter regimen (p = 0.006). The longer regimen was independently associated with favorable outcomes (adjusted odds ratio 1.58, 95% CI 1.15-2.17; p = 0.004).
Conclusions:
Baseline demographic and clinical characteristics were broadly comparable, although resistance profiles differed because regimen allocation was guided by drug susceptibility testing and programmatic eligibility criteria.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration